Carryover co-operation
Sir Mene Pangalos of AstraZeneca, in a Cambridge Judge interview, urges continuation of the 'exceptional' collaboration between industry, academia, government and regulators that led to rapid development of COVID-19 vaccines. Sir Mene Pangalos The "exceptional" collaboration between the pharmaceutical industry,…
Biopharm expansion
Apollo Therapeutics, a life sciences company led by Cambridge Judge Business School alumnus and Fellow Dr Richard Mason, completes $145 million financing. Apollo Therapeutics, a biopharmaceutical company headed by Cambridge Judge Business School MBA alumnus and Fellow Dr Richard Mason…
United Press International: Study: Second opinion can reduce risk for long-term opioid use
A study looking at opioid use co-authored by Stefan Scholtes, Dennis Gillings Professor of Health Management at Cambridge Judge Business School, featured in United Press International. The study found that “a “second opinion” by another prescribing doctor within 30 days…
Opioid intervention
'Second opinion' by another prescribing doctor within 30 days of an opioid prescription reduces long-term opioid use by 31%, concludes a new study led at Cambridge Judge Business School. A "second opinion" by another prescribing doctor within 30 days of…
Stock sales
Three US senators cite research by Professor Alan Jagolinzer of Cambridge Judge Business School in urging SEC reform of insider trading laws. Professor Alan Jagolinzer Three US senators cited research co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in urging the Securities…
Good reporting
Annual reports should inform society – not just shareholders – about vital issues such as the financial health and environmental impact of organisations, says Professor Alan Jagolinzer of Cambridge Judge Business School. Professor Alan Jagolinzer By Professor Alan Jagolinzer Corporate…
Forbes India: How drug companies can increase their R&D effectiveness
A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…
Call for SEC action
Article co-authored by Professor Alan Jagolinzer of Cambridge Judge calls for Securities and Exchange Commission to reform 'pre-planned' stock sale rules. Professor Alan Jagolinzer An article co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in The Hill, a…
Cambridge Network: Study examines cultural fit in big pharma integration
Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. “As I progressed through my EMBA programme in 2018-2019, the BMS acquisition of Celgene was announced…
Big pharma
Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. Piyush Durani The well-known business expression "culture eats strategy for breakfast" is particularly apt for mergers…
